[Inhibition of platelet aggregation: experimental findings and clinical prospects].
D000893:Anti-Inflammatory Agents / Q000494:pharmacology; D000928:Antidepressive Agents / Q000494:pharmacology; D001777:Blood Coagulation / Q000187:drug effects*; D001792:Blood Platelets / Q000187:drug effects*; D002110:Caffeine / Q000494:pharmacology; D002994:Clofibrate / Q000627:therapeutic use; D003911:Dextrans / Q000627:therapeutic use; D004176:Dipyridamole / Q000627:therapeutic use; D004837:Epinephrine / Q000037:antagonists & inhibitors; D006493:Heparin / Q000494:pharmacology; D006801:Humans; D066298:In Vitro Techniques; D009705:Nucleosides / Q000494:pharmacology; D010629:Phenformin / Q000627:therapeutic use; D010973:Platelet Adhesiveness / Q000187:drug effects; D011453:Prostaglandins / Q000494:pharmacology; D011743:Pyrimidines / Q000494:pharmacology; D012459:Salicylates / Q000627:therapeutic use; D012701:Serotonin / Q000494:pharmacology; D013923:Thromboembolism / Q000188:drug therapy; D013927:Thrombosis / Q000503:physiopathology / Q000517:prevention & control
D000893:Anti-Inflammatory Agents; D000928:Antidepressive Agents; D003911:Dextrans; D009705:Nucleosides; D011453:Prostaglandins; D011743:Pyrimidines; D012459:Salicylates; D012701:Serotonin; D002110:Caffeine; D004176:Dipyridamole; D006493:Heparin; D010629:Phenformin; D002994:Clofibrate; D004837:Epinephrine
L'inhibition de l'agrégation plaquettaire: données expérimentales et perspectives cliniques.